Gilead Sciences, Inc. has announced the presentation of new findings from its antiviral research and development programs at IDWeek 2024, scheduled for October 16-19. The presentations will include data from…
Pfizer Inc. (NYSE: PFE) has announced encouraging topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)…
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in adults…
AstraZeneca’s Airsupra (albuterol/budesonide) has demonstrated promising outcomes in the BATURA Phase IIIb trial, achieving its primary endpoint by significantly and meaningfully reducing the risk of severe asthma exacerbations when used…
Roche (SIX: RO, ROG; OTCQX: RHHBY) presented promising two-year findings from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, held from October 8-12, 2024. The study…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Itovebi™ (inavolisib) for use in combination with palbociclib (Ibrance®) and fulvestrant to treat…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced plans to present new research at IDWeek 2024 in Los Angeles, CA, from October 16-19. The company…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced today that its Phase 3 KEYNOTE-689 trial met the primary endpoint of event-free survival (EFS) for KEYTRUDA®…
SSegal Trials is proud to have played a significant role in the FDA approval of COBENFY™ (xanomeline and trospium chloride), a pioneering first-in-class muscarinic agonist developed by Bristol Myers Squibb…
The AIDS Healthcare Foundation (AHF) has expressed support for Gilead’s recent decision to expand the availability of lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with…
Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for adult patients with resectable non-small cell lung cancer (NSCLC) characterized by…
Marshall B. Ketchum University (MBKU) recently celebrated the outstanding achievements of its alumni at the 2024 Distinguished Alumni Awards Ceremony, held during its second annual homecoming event. This year, the…